Alzheimer’s Disease Clinical Trials Program at Cedars-Sinai | sciencenewsnet.in

Breaking News

Could the liver hold the key to better cancer treatments?

Study opens new avenue for immunotherapy drug development

New York State, City and Bronx Borough Officials Celebrate the 125th Anniversary of the Bronx Zoo

Silent flight edges closer to take off, according to new research

A Common Pathway in the Brain That Enables Addictive Drugs to Hijack Natural Reward Processing Has Been Identified by Mount Sinai

Novel material supercharges innovation in electrostatic energy storage

MSU expert to attend oral arguments in SCOTUS case that could turn homelessness into a crime

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the Advancement of Science

Hubble Goes Hunting for Small Main Belt Asteroids

19 Apr, 2024

MEDIA ADVISORY: Cedars-Sinai Experts On Hand to Discuss New Alzheimer’s Drug Now Under Review

January 6, 2023 sarah JonasFeature Expert

The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.